Phase III · TRIUMPH Program
Obesity is a treatable disease — not a failure of willpower.
Retatrutide marks the biochemical paradigm shift: the first triple-agonist that simultaneously regulates satiety, insulin sensitivity and basal metabolic rate.
Treatment available
Request a personal consultation
We offer this treatment – free initial consultation.
Benchmark
-24%
Average weight loss after 48 weeks on Retatrutide in Phase II. Reference: Semaglutide ~15%, Tirzepatide ~22%.
Generations
Gen 1Semaglutid
~15 %
Gen 2Tirzepatid
~22 %
Gen 3Retatrutid
~24 %
Read next
Guide for expats in Thailand
Availability, prices in Baht and Bangkok hospitals for GLP-1 therapy.
Head-to-head comparison
Retatrutide vs Semaglutide vs Tirzepatide — efficacy, mechanism, approval.
Approval status 2026
Timeline for FDA, EMA and BfArM plus details on the TRIUMPH-1 trial.
Frequently asked (FAQ)
Concise answers to the most common questions about Retatrutide.